This early-stage study is testing the safety of a single spinal injection called RJK002 in people with ALS. The trial involves 9 participants who were diagnosed within the last 2 years and still have good breathing and movement function. Researchers will monitor for side effects …
Phase: PHASE1 • Sponsor: RJK Biopharma Ltd • Aim: Disease control
Last updated Mar 30, 2026 14:32 UTC